title: Clinical course of concomitant Hbv and Hcv infection in renal allograft recipients.
abstract: We evaluated the impact of concomitant infection with Hepatitis B virus (HBV) and Hepatitis C virus (HCV) on the clinical course after renal transplantation (Tx). In 335 patients (pts) transplanted between 1991 and 1993 we found 30 (9%) recipients who were positive for Hepatitis B surface antigen (HBsAg) (ELISA, Organon) and anti-HCV antibodies (immunoblot assay Lia Tek) preTx. Chronic liver disease (CLD) (two-fold or greater increase in serum ALT and AST levels for at least six months) developed in 40.7% coinfected pts as compared to 24.4% and 25.7% pts infected only with HCV or HBV, respectively. Maintenance immunosuppression consisted of P + Aza + CsA, mean follow-up time was 28 +/- 15 months. The mean time of the onset of CLD was 3.0 months (range: 1-18 months) after Tx. Percutaneous liver biopsy performed in 5 CLD pts revealed chronic active hepatitis (CAH) in 4 and chronic persistent hepatitis (CPH) in 1 pt. Four pts who had CAH and were positive for HCV RNA (RT PCR) in serum and for HBcAg in liver tissue, received interferon-alpha therapy for 6 months. Clinical improvement of liver function was observed in all of them, but none cleared HBsAg or HCV RNA. One pt lost his graft due to acute rejection. Concomitant infection with HBV and HCV is associated with the high risk of development of CLD early after Tx. We recommend that pretransplant evaluation of both anti-HCV and HBsAg positive pts should include liver biopsy to exclude potential recipients with CAH.
authors.affiliation: Transplantation Institute, Warsaw Medical School.
authors.forename: M
authors.initials: M
authors.lastname: Durlik
authors.forename: Z
authors.initials: Z
authors.lastname: Gaciong
authors.forename: L
authors.initials: L
authors.lastname: Soluch
authors.forename: Z
authors.initials: Z
authors.lastname: Rancewicz
authors.forename: D
authors.initials: D
authors.lastname: Rowińska
authors.forename: B
authors.initials: B
authors.lastname: Kozłowska-Boszko
authors.forename: J
authors.initials: J
authors.lastname: Wyzga
authors.forename: B
authors.initials: B
authors.lastname: Walewska-Zielecka
authors.forename: W
authors.initials: W
authors.lastname: Rowiński
authors.forename: J
authors.initials: J
authors.lastname: Szmidt
authors.forename: M
authors.initials: M
authors.lastname: Lao
mesh_terms: D000328:Adult; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology; D018937:Hepatitis C Antibodies / Q000097:blood; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000503:physiopathology*; D015995:Prevalence; D012189:Retrospective Studies
chemical_list: D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D018937:Hepatitis C Antibodies; D007166:Immunosuppressive Agents